Explore the vast range of titles available.

Despite the effectiveness of pre-exposure prophylaxis (PrEP) in reducing HIV incidence, this intervention is inaccessible in Iran. We examined the interest in using PrEP and associated factors among people who inject drugs (PWID) in 2023 using data from 2,174 PWID. The main outcome was interest in using PrEP, which was divided into three categories: interest in using PrEP under any circumstances, interest in using PrEP if provided for free, and no interest in using PrEP. We found that 37.9% of PWID were interested in using PrEP under any circumstances, 48.3% were interested in using PrEP if provided for free, and 13.8% were not interested in using PrEP. Additionally, only 7.7% of participants reported prior awareness of PrEP. Having high school or more education (adjusted relative risk ratios [ARRR]: 1.92; 95% confidence interval [CI]: 1.42, 2.61), having access to opioid agonist treatment (OAT) in the last six months (ARRR: 1.59; 1.13, 2.25), and having sufficient HIV knowledge (ARRR: 2.87; 2.03, 4.06) were positively associated with interest in using PrEP under any circumstances. Similarly, having high school or more education (ARRR: 1.50; 1.10, 2.04), having access to OAT in the last six months (ARRR: 2.63; 1.88, 3.67), and having sufficient HIV knowledge (ARRR: 4.53; 3.23, 6.37) were associated with interest in using PrEP if provided for free. Health insurance was negatively associated with interest in using PrEP under any circumstances (ARRR: 0.64; 0.47, 0.87) and with interest in using PrEP if provided for free (ARRR: 0.33; 0.23, 0.45). The findings show a strong potential for PrEP acceptance, indicating that addressing financial and logistical barriers to free PrEP access could greatly reduce HIV incidence among PWID in Iran.

Patients with beta-thalassemia (BT) are susceptible to psychological disorders such as depression. The present study was conducted to estimate the pooled prevalence of depression among patients with BT in Iran. Domestic and international databases were searched for relevant articles published from 1991 until June 2019. We searched international databases such as Scopus, ISI, and Embase; Iranian databases such as SID, Magiran, and IranDoc; and Google Scholar and PubMed search engines. The MeSH keywords used were \"depression\", \"mental health\", \"depressive disorder\", \"thalassemia\", \"beta-thalassemia major\", \"prevalence\", \"epidemiology\", and \"Iran\". Relevant cross-sectional or cohort studies were included in the analysis. Cochran's test and the index were used to assess heterogeneity. The pooled prevalence and its 95% confidence interval (CI) were calculated using \"metaprop\" commands in Stata 14. In cases, where the statistic was greater than 50%, the random-effects model was used. Eighteen eligible studies were included. The pooled prevalence of depression was 42% (95% CI: 33% to 52%), whereas the pooled prevalence of mild, moderate, severe, and extremely severe depression was 16% (95% CI: 11% to 22%), 13% (95% CI: 9% to 18%), 13% (95% CI: 9% to 17%), and 3% (95% CI: 0% to 8%), respectively. The pooled prevalence of depression in moderate- and high-quality studies was 45% (95% CI: 29% to 61%), and 39% (95% CI: 27% to 51%), respectively. The high prevalence of depression highlights the urgent need for the establishment of interventions for the prevention, early detection, and treatment of depression among Iranian patients with BT.

Objective: Women with breast cancer (BC) may have dreadful experiences mainly because of the severity of their disease, the complications of treatments, and its psychological burden. In this study, we explored the concerns of BC cases in Iran. Therefore, this study aimed to investigate the problems of BC patients from the beginning of treatment and its continuation in Kerman city. Methods: This qualitative descriptive–explorative study was conducted using a conventional content analysis approach to investigate the concerns of women with BC during their therapy in Iran. A total of 30 women with BC were included in the study through purposive sampling. Data were collected through in‐depth, semi‐structured interviews. The study process lasted from November 2019 to December 2022. Results: Three hundred and twenty codes, 1 main category, 3 categories, and 16 subcategories were extracted. Based on the participants’ experiences, women with BC face various concerns during their treatment: (1) physical and psychological problems, (2) family and social problems, and (3) organizational problems. Conclusion: This study shows that most of the concerns of BC are related to psycho‐emotional problems, easy access to medicine and treatment costs, and other economic problems. This clearly shows the urgent need of these patients for regular counseling and follow‐up and more support in the field of financing. Addressing concerns before treatment, particularly among women who are considered a vulnerable group in society, can assist researchers and specialists in planning counseling and necessary follow‐ups to reduce these patients’ anxiety and support their rehabilitation after treatment. Attention to the necessary psychological and social support for these patients may also help improve their adaptation.